Aug 16 (Reuters) - Seagen said on Wednesday its cancer therapy in combination with Roche's Kadcyla helped control disease progression in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,194 INR | +1.22% | +1.54% | 2.3B | ||
2,686 PTS | +0.86% | +0.34% | - | ||
221 CHF | +1.01% | -0.50% | 195B | ||
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |